IRIDEX Corporation (IRIX) |
| 0.9344 -0.017 (-1.75%) 07-17 16:00 |
| Open: | 0.92 |
| High: | 0.9499 |
| Low: | 0.92 |
| Volume: | 22,820 |
| Market Cap: | 16(M) |
| PE Ratio: | -4.92 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.20 |
| Resistance 1: | 1.08 |
| Pivot price: | 1.09 |
| Support 1: | 0.89 |
| Support 2: | 0.74 |
| 52w High: | 1.65 |
| 52w Low: | 0.87 |
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
| EPS | -0.190 |
| Book Value | -0.070 |
| PEG Ratio | 0.94 |
| Gross Profit | 1.086 |
| Profit Margin (%) | -6.23 |
| Operating Margin (%) | -2.75 |
| Return on Assets (ttm) | -5.4 |
| Return on Equity (ttm) | -56.5 |
Tue, 14 Jul 2026
IRIDEX CORP (IRIX) grants CFO 30K RSUs and 170K options - Stock Titan
Mon, 13 Jul 2026
Iridex Corp (Nasdaq: IRIX) investor group reports 29.92% ownership stake - Stock Titan
Mon, 13 Jul 2026
Novel Inspiration International Co Ltd Intends to Engage with IRIDEX Corporation - marketscreener.com
Wed, 08 Jul 2026
Novel Inspiration gains IRIDEX (IRIX) shares as quarterly note interest - Stock Titan
Tue, 09 Jun 2026
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference - GlobeNewswire
Mon, 08 Jun 2026
Iridex CFO Dizon purchases $2,899 of common stock - Investing.com
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |